
Oxford Nanopore Technologies has delivered a sharp rebound over the past year, which puts fresh focus on whether the current share price lines up with the cash the business is expected to generate. With growing attention on its sequencing platform and data capabilities, the central question for investors is how that story translates into intrinsic value based on its cash flows.
The stock's next move may depend on whether today's price is justified by Oxford Nanopore Technologies' cash flows when compared with its Discounted Cash Flow (DCF) intrinsic value estimate.
If you want to test the same cash flow question that hangs over Oxford Nanopore Technologies across a wider group, scan through 16 high quality undervalued stocks.
The Discounted Cash Flow (DCF) method here asks whether the future cash Oxford Nanopore Technologies might produce is enough to justify the current £2.00 share price. The latest twelve month Free Cash Flow sits at a loss of about £117.8 million, so the whole exercise rests on expectations that the business can shift from cash burn to meaningful positive inflows over time.
Analyst projections in this DCF profile assume Free Cash Flow keeps recovering across the coming decade, with the model turning positive by 2030 and then building from there. That points to a story where Oxford Nanopore Technologies is treated less like a mature earner and more like a platform that could scale cash generation if BioPharma, Clinical and AI related uses of its data convert into paying activity. Because the recent AI optionality news has arrived while the DCF still places estimated intrinsic value substantially above the current price, the gap suggests the market is yet to fully price in those longer range cash flow expectations. Find out what Oxford Nanopore Technologies could be worth using our Discounted Cash Flow (DCF) estimate.
Simply Wall St Narratives for Oxford Nanopore Technologies sit on the Community page and extend the cash flow puzzle by explaining what would need to happen to growth, margins and earnings for the shares to be worth significantly more or less than they are today. Each scenario links its valuation number to a clear view of how Oxford Nanopore Technologies' scale, profitability path and key risks might evolve, which you can revisit as fresh information becomes available.
A written, number driven view on Oxford Nanopore Technologies gives you a clear set of assumptions on cash generation and valuation that can be checked against actual outcomes as they land. With recent attention on AI related opportunities and the new India Genomics Centre of Excellence, a structured narrative helps you track whether these developments translate into the kind of cash flows implied by today's price.
Share your own Narrative for Oxford Nanopore Technologies and set out the assumptions behind your valuation.
The cash flow story only goes so far without looking at who sets the course, how their interests line up with yours, and what they are actually paid to deliver. See who runs Oxford Nanopore Technologies and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com